Atrial natriuretic peptide single nucleotide polymorphisms in patients with nonfamilial structural atrial fibrillation

Clinical Medicine Insights: Cardiology

Volumn 7, Issue , 2013, Pages 153-159

  Francia, Pietro ^a   Ricotta, Agnese ^a   Frattari, Alessandra ^a   Stanzione, Rosita ^a   Modestino, Anna ^a   Mercanti, Federico ^a   Adduci, Carmen ^a   Sensini, Isabella ^a   Cotugno, Maria ^b   Baila, Cristina ^a   Rubattu, Speranza ^a,b   Volpe, Massimo ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS NEUROMED   (Italy)

Author keywords

Atrial fibrillation; Atrial natriuretic peptide; Gene variants

Indexed keywords

AMINO TERMINAL PRO ATRIAL NATRIURETIC PEPTIDE; ATRIAL NATRIURETIC FACTOR; NATRIURETIC FACTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CAUCASIAN; CLINICAL FEATURE; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOTYPE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART LEFT ATRIUM; HETEROZYGOTE; HUMAN; HYPERTENSION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; PATHOPHYSIOLOGY; PROTEIN BLOOD LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84884363016     PISSN: 11795468     EISSN: 11795468     Source Type: Journal    
DOI: 10.4137/CMC.S12239     Document Type: Article

References (29)

1. Chugh SS, Blackshear JL, Shen WK, Hammill SC, Gersh BJ. Epidemiology and natural history of atrial fibrillation: clinical implications. J Am Coll Cardiol. 2001;37(2):371-8.
2. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998;82(8A):2N-9.
3. Furlanello F, Lupo P, Pittalis M, et al. Radiofrequency catheter ablation of atrial fibrillation in athletes referred for disabling symptoms preventing usual training schedule and sport competition. J Cardiovasc Electrophysiol. 2008;19(5):457-62.
4. Fox CS, Parise H, D'Agostino RB, et al. Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. JAMA. 2004;291(23):2851-5.
5. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med. 1995;98(5):476-84.
6. Cody RJ, Atlas SA, Laragh JH, et al. Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J Clin Invest. 1986;78(5): 1362-74.
7. Lynch Al, Claas SA, Arnett DK. Areview of the role of atrial natriuretic peptide gene polymorphisms in hypertension and its sequelae. Curr Hypertens Rep. 2009;11(1):35-42.
8. Gruchala M, Ciecwierz D, Wasag B, et al. Association ofthe Seal atrial natriuretic peptide gene polymorphism with nonfatal myocardial infarction and extent of coronary artery disease. AmHeartJ. 2003;145(1): 125-31.
9. Rubattu S, Bigatti G, Evangelista A, et al. Association of atrial natriuretic peptide and type a natriuretic peptide receptor gene polymorphisms with left ventricular mass in human essential hypertension. J Am Coll Cardiol. 2006;48(3):499-505.
10. Barbato E, Bartunek J, Mangiacapra F, et al. Influence of rs5065 atrial natriuretic peptide gene variant on coronary artery disease. J Am Coll Cardiol. 2012;59(20): 1763-70.
11. Rubattu S, Stanzione R, Di Angelantonio E, et al. Atrial natriuretic peptide gene polymorphisms and risk of ischemic stroke in humans. Stroke. 2004;35(4):814-8.
12. Ren X, Xu C, Zhan C, et al. Identification of NPPA variants associated with atrial fibrillation in a Chinese GenelD population. Clin Chim Acta. 2010;411(7-8):481-5.
13. Roberts JD, Davies RW, Lubitz SA, et al. Evaluation of non-synonymous NPPA single nucleotide polymorphisms in atrial fibrillation. Europace. 2010;12(8):1078-83.
14. Ramasawmy R, Kotea N, Lu CY, Sayada C, Baligadoo S, Krishnamoorthy R. Investigation ofthe polymorphic Seal site by a PCR-based assay at the human atrial natriuretic peptides (hANP) gene locus. Hum Genet. 1992;90(3):323-1.
15. Rubattu S, Ridker P, Stampfer MJ, Volpe M, Hennekens CH, LindpaintnerK. The gene encoding atrial natriuretic peptide and the risk of human stroke. Circulation. 1999;100(16):1722-6.
16. Rubattu S, Evangelista A, Barbato D, et al. Atrial natriuretic peptide (ANP) gene promoter variant and increased susceptibility to early development of hypertension in humans. J Hum Hypertens. 2007;21(10):822-4.
17. Camm AJ, Kirchhof P, Lip GY, et al. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369-429.
18. Fuster V, Rydén LE, Asinger RW, et al. American College of Cardiology/ American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation); North American Society of Pacing and Electrophysiology ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology. Circulation. 2001;104(17):2118-50.
19. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-121.
20. Neal B, MacMahon S. The World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration: prospective collaborative overviews of major randomized trials of blood pressure-lowering treatments. Curr Hypertens Rep. 1999;1(4):346-56.
21. Puavilai G, Chanprasertyotin S, Sriphrapradaeng A. Diagnostic criteria for diabetes mellitus and other categories of glucose intolerance: 1997 criteria by the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (ADA), 1998 WHO consultation criteria, and 1985 WHO criteria. World Health Organization. Diabetes Res ClinPract. 1999;44(l):21-6.
22. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantita-tion of the left ventricle by two-dimensional echocardiography American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989;2(5):358-67.
23. de Simone G, Daniels SR, Devereux RB, et al. Left ventricular mass and body size innormotensive children and adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol. 1992;20(5): 1251-60.
24. Verdecchia P, Carini G, Circo A, et al. MAVI (MAssa Ventricolare sinistra nell'Ipertensione) Study Group. Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study. J Am Coll Cardiol. 2001;38(7):1829-35.
25. Kato N, Sugiyama T, Morita H, et al. Genetic analysis of the atrial natriuretic peptide gene in essential hypertension. Clin Sci. 2000;98(3):251-8.
26. Tsai CT, Lai LP, Hwang JJ, Lin JL, Chiang FT. Molecular genetics of atrial fibrillation. J Am Coll Cardiol. 2008;52(4):241-50.
27. Hodgson-Zingman DM, Karst ML, Zingman LV, et al. Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation. N Engl J Med. 2008;359(2):158-65.
28. Sciarretta S, Marchitti S, Bianchi F, et al. C2238 atrial natriuretic peptide molecular variant is associated with endothelial damage and dysfunction through natriuretic peptide receptor C signaling. CircRes. 2013;112(10):1355-64.
29. Lynch AL, Boerwinkle E, Davis BR, et al. Pharmacogenetic association of the NPPAT2238C genetic variant with cardiovascular disease outcomes in patients with hypertension. JAMA. 2008;299(3):296-307.